NCT00080509View on ClinicalTrials.gov

Effectiveness of KOS-862 in the Treatment of Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

November 30, 2004

Conditions
Lung Cancer
Interventions
DRUG

KOS-862

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY